In the Margins

Valeant names hedge fund partner to board

October 26, 2015

By Forbes

Valeant Pharmaceuticals has named Mason Morfit, a partner at activist hedge fund ValueAct Capital, to its board of directors. Morfit previously served on the embattled specialty drugmaker's board from 2007 to 2014; ValueAct is one of Valeant's largest shareholders. Read the original story from Forbes

 

 

Most Read

10 Things
10 Things...to ask about investing in China

Investing in China is complex, whether a mutual fund offers direct exposure to China and the region or provides access via Chinese companies' U.S.-listed American depositary ...